Your browser doesn't support javascript.
loading
T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
Quist-Paulsen, P; Toft, N; Heyman, M; Abrahamsson, J; Griskevicius, L; Hallböök, H; Jónsson, Ó G; Palk, K; Vaitkeviciene, G; Vettenranta, K; Åsberg, A; Frandsen, T L; Opdahl, S; Marquart, H V; Siitonen, S; Osnes, L T; Hultdin, M; Overgaard, U M; Wartiovaara-Kautto, U; Schmiegelow, K.
Afiliación
  • Quist-Paulsen P; Department of Hematology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. Petter.Quist-Paulsen@ntnu.no.
  • Toft N; Department of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.
  • Heyman M; Childhood Cancer Research Unit, Karolinska Institute, Astrid Lindgren's Childrens' Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Abrahamsson J; Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Griskevicius L; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
  • Hallböök H; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Jónsson ÓG; Children's Hospital, Landspitali University Hospital, Reykjavík, Iceland.
  • Palk K; Department of Hematology, North Estonia Medical Centre, Tallinn, Estonia.
  • Vaitkeviciene G; Centre for Pediatric Oncology and Hematology, Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius University, Vilnius, Lithuania.
  • Vettenranta K; Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
  • Åsberg A; Department of Pediatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Frandsen TL; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Opdahl S; Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNU, Trondheim, Norway.
  • Marquart HV; Department of Clinical Immunology, Section 7631, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Siitonen S; Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.
  • Osnes LT; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Hultdin M; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
  • Overgaard UM; Department of Hematology, The University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Wartiovaara-Kautto U; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Schmiegelow K; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
Leukemia ; 34(2): 347-357, 2020 02.
Article en En | MEDLINE | ID: mdl-31611626
The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Guideline Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Guideline Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Reino Unido